{"name":"PharmaMar","slug":"pharmamar","ticker":"","exchange":"","domain":"","description":"PharmaMar is a Spanish pharmaceutical company headquartered in Colmenar Viejo, Madrid, Spain. Founded in 1986 as a subsidiary of Zeltia, it absorbed its parent company and all its subsidiaries in a reverse merger takeover in 2015. The company is a component of the Madrid Stock Exchange General Index (IGBM) and the IBEX 35 since 2020, after being part of the Ibex Small Cap stock market index.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Gemcitabine plus PM060184","genericName":"Gemcitabine plus PM060184","slug":"gemcitabine-plus-pm060184","indication":"Other","status":"phase_1"},{"name":"PM060184","genericName":"PM060184","slug":"pm060184","indication":"Other","status":"phase_2"},{"name":"Vincristine (VCR)","genericName":"Vincristine (VCR)","slug":"vincristine-vcr","indication":"Other","status":"phase_3"},{"name":"Zalypsis","genericName":"Zalypsis","slug":"zalypsis","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Aplidin®","genericName":"Aplidin®","slug":"aplidin","indication":"Relapsed or refractory multiple myeloma","status":"phase_2"}]}],"pipeline":[{"name":"Aplidin®","genericName":"Aplidin®","slug":"aplidin","phase":"phase_2","mechanism":"Aplidin is a chemotherapeutic agent that works by inhibiting the enzyme histone deacetylase (HDAC).","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"Gemcitabine plus PM060184","genericName":"Gemcitabine plus PM060184","slug":"gemcitabine-plus-pm060184","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PM060184","genericName":"PM060184","slug":"pm060184","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Vincristine (VCR)","genericName":"Vincristine (VCR)","slug":"vincristine-vcr","phase":"phase_3","mechanism":"Vincristine works by inhibiting microtubule formation in the mitotic spindle, resulting in cell cycle arrest at metaphase.","indications":[],"catalyst":""},{"name":"Zalypsis","genericName":"Zalypsis","slug":"zalypsis","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxOVHNzcTZqWnRvSDRvdEJJb29HTmJuQ2gtRU5mSGZIN01ua0o4elJDWnRRNVh1TE04UC04UlhrWWJPNnVOQ1VwQ1BNeUgxNlF2aFVsZTdkTko2cFVzQXpCSlQtM1ZFMG5CcERyYUY1d21yaHU3ODVadGZsSHp1Y3hlcE5ibXBJV1FkUkRfVHFsTk82U19DQWhILVVEdGMzNnhPSjNMenlOalVvZmhUOFZjYnhyb0FKOFBkbDR6ZXhneUlHazlFWU5lVHNWbjRGc0VBczE2bzREeHZTM3lLWjkzR1lR?oc=5","date":"2026-03-24","type":"regulatory","source":"BioSpectrum Asia","summary":"Taiwan approves PharmaMar’s treatment for small cell lung cancer as first-line maintenance therapy - BioSpectrum Asia","headline":"Taiwan approves PharmaMar’s treatment for small cell lung cancer as first-line maintenance therapy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOZkYtNUxTZ2dIS1JkYzZIdlNFQ0k3RlYxa2FhVEh0THlXX09hb28wMmUwek9pSk1uZXI2M1lLN215cVd0TUlzVGNpcV93TWtvZUJXeUc5MkYyRVo2MVRIdkRwN0NKVnpZVXdmRzVXN0JzdXNPZU9EeWNzMG9BRmphQ2FPdWJJNjRUdDZCMjNzak1kVjE3dWotNDJqMnRISlppRWZzRlpFaVdfVV9PWEJ5RA?oc=5","date":"2026-03-24","type":"pipeline","source":"TipRanks","summary":"Pharma Mar Launches Employee Share Plan From Treasury Stock - TipRanks","headline":"Pharma Mar Launches Employee Share Plan From Treasury Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNWW9LYi1iU2RndlJRSTgwNW9fVXg4endLRmFheHFRTUtXa1duVFpwQ2dZRXdvSEdkOE1zajkyNkhzRDFkb2hEUkRycEppM1FCUlB4QTF2dTYyS3MzTTNCZHN0Rkl6ak1ieXBDVnB0VlR4dmo1cjIwVGhHMktwWmNaVW00b2JMS0JkQlphNHRMcXloSm55UzdvZkROcm45LW91dUE?oc=5","date":"2026-02-18","type":"patent","source":"Bloomberg Law News","summary":"J&J, Pharma Mar Agree to End Patent Suits on Two Yondelis Copies - Bloomberg Law News","headline":"J&J, Pharma Mar Agree to End Patent Suits on Two Yondelis Copies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFA2TUhMcUhmTm5xLWxtQUJiMjV0RE0wWFlEMmhzNTVvN0JaMWVEUmQzZFJVUnJ6eXBhbHFYMUFNb09YVEIxNzRwUm9qdS1nM1RmNUJnUDl4RjFVOHBPSUlxcWgxUk1DMGgtWGFjei1xZnJYcmxkS0VUQ0x1Zw?oc=5","date":"2026-01-23","type":"pipeline","source":"tikr.com","summary":"Pharma Mar Stock Outlook: A Path to 40% Returns - tikr.com","headline":"Pharma Mar Stock Outlook: A Path to 40% Returns","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-19","type":"earnings","source":"simplywall.st","summary":"Surging Zepzelca Royalties and Profitability Could Be A Game Changer For Pharma Mar (BME:PHM) - simplywall.st","headline":"Surging Zepzelca Royalties and Profitability Could Be A Game Changer For Pharma Mar (BME:PHM)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-02","type":"pipeline","source":"simplywall.st","summary":"Pharma Mar, S.A. (BME:PHM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st","headline":"Pharma Mar, S.A. (BME:PHM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxNdEtMYVE1V1BQWVQ2VFJycXRmR2dHLV9lY0lmWXdPSXQ4bWtBMHlBaXptNkM1MHB5bHU2U2pUUkVGZ1ppQ210R2ZUOHVORG5Pc1VXRE91bUMzUGxyX0ZSa0VBRHJqRmlPaTBwUDd4SUZvSmdseUxwbGtNb3BTaWRSQUxNZ0xKVTQ4RGx6UHFSZTdxSWo1b3VnUG5mUTlRLWlOQ18ySjZDV2w1NkRyZXNpTDRhU0lYZWp6dTJ5UjZlVzFPR1RtYjE4REhTeThvcjUtc3N1V19GLUNKS2FQZ2NvUi1HaTVReEFNVWhGMXlqc3lNQWlmNEE?oc=5","date":"2025-10-16","type":"regulatory","source":"The Corner .eu","summary":"Pharmamar receives $50 million from Jazz Pharma for approval of Zepzelca + Tecentriq combo treatment for small cell lung cancer - The Corner .eu","headline":"Pharmamar receives $50 million from Jazz Pharma for approval of Zepzelca + Tecentriq combo treatment for small cell lung","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxOV1hEdWoyZGIxM1M5MkZ1aUM3MlllbDczdGRabzdHS2h5QUhwTkdGUU41UUp6QjJJeGVIR2ZDNHVHWU0zSFFuUnVxRGJEVjVFdmVaX09DaklYQy0zSEZpN2x6bEw3M2ZuWTlFZFBDOWdiV2U4TFhJZWE2aHpoMk82RTZybVBCclVCc2hENUljVEZNRDJRNEY0b2syWVUzLWRIampVMkhVdFFLR3JVekRWcUpvaW1KV0RYYlNkdkswcENfclJBdmNXZW14SGo?oc=5","date":"2025-10-03","type":"regulatory","source":"The Corner .eu","summary":"FDA approves Zepzelca (Pharma Mar) + Tecentriq (Roche) combination therapy for treating lung cancer - The Corner .eu","headline":"FDA approves Zepzelca (Pharma Mar) + Tecentriq (Roche) combination therapy for treating lung cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE14dlQyYlNoRlZJUVdJMVNPZEhGdlNMM3RpbmhueXhXY01lTlQ2ZENkcDJkMXN1VGhVSDhkT0RDSXB2RGdoRkp6a0c1OG9NZzR4Mmhj?oc=5","date":"2025-10-02","type":"pipeline","source":"FirstWord Pharma","summary":"Jazz, PharmaMar's Zepzelca cleared in US for first-line maintenance of ES-SCLC with Tecentriq - FirstWord Pharma","headline":"Jazz, PharmaMar's Zepzelca cleared in US for first-line maintenance of ES-SCLC with Tecentriq","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOUkhwRkhWdjVYRWl0RlBfaHdRSWdpT1dKY1Z0Z1hNSE5sWF92MGhYTzhnckxCM3N4YlRkVlE3VGJIdzV3TGt1Z1otWXJpbTQ3SUV5UmR6RmJFa09lMWhJTkpseGZFUjJQdTdXLUNzMGFxanh2dUtGX1RZWl94YkV3dWV0emQ?oc=5","date":"2025-05-26","type":"trial","source":"pharmaphorum","summary":"ASCO 25: Jazz, PharmaMar reveal SCLC survival data - pharmaphorum","headline":"ASCO 25: Jazz, PharmaMar reveal SCLC survival data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5iNldGYUZwcnBIQ04tZ3JlTTJaem5ra1hOcC0ya09qek14akx6NGpxNnNWcWl5Q0pkWjJyWG1wakZ0ZlFINTZhOHl1UzdOcEs2cFg4?oc=5","date":"2025-05-22","type":"pipeline","source":"FirstWord Pharma","summary":"ASCO25: Jazz, PharmaMar drug combo delivers survival boost in SCLC - FirstWord Pharma","headline":"ASCO25: Jazz, PharmaMar drug combo delivers survival boost in SCLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxORVd2SVY2WVMxYVlCLWpMVjVyV09KX2Z6a1R4YlNONHVUQlhWbExkUkRQd1ctSjludDNvMVlHR0w3UEJrTUVZZU52bVliWm9IdVRnclgyVGpmeUVYbnBpUnF4dXdZLVVuOUNCOEswcmhxbWtGN2xyeU5qNm5KSkdIS3FDRDFvSEt2SXZZNnJDYVNmWkJGZ3oybWI3cnZVNnhQTDhteU51Ump0YXBlTll6OGNqUE5rMUczejVWUzdYRFROdmRReHJHREJiajBITWVrT2pJcnU4QmwyNG1RVGdWei1SR1ZjQQ?oc=5","date":"2019-12-19","type":"deal","source":"PR Newswire","summary":"PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S. - PR Newswire","headline":"PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S.","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_2":3,"phase_1":1,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}